Li Fraumeni syndrome, characterized by germline TP53 mutations, remains the prototypical hereditary condition that predisposes patients to MDS or AML (3–5% life-time risk), though somatic TP53 mutations also play a role. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.